Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (645)	3/28/1999 5:19:00 PM
From: Captain Jack	Respond to of 942

Tony--- good earnings and rev growth would make the biggest difference imo,,, the agph deal is figured already...

To: Anthony Wong who wrote (645)	3/28/1999 9:10:00 PM
From: Captain Jack	Read Replies (1) \| Respond to of 942

Tony--- speaking of CELXA,,, bad news for Lilly but...... Depressing news for Lilly's Prozac . . . NEW YORK (CBS.MW) -- Merrill Lynch is singing the blues about Prozac, cutting its revenue expectations from Eli Lilly's (LLY) anti-depressant on concerns rival drug Celexa threatens to take a 19 percent market share within three years. Sales of Celexa, the anti-depressant developed by Forest Labs (FRX) and co-marketed by Warner-Lambert (WLA), could exceed $1 billion in 2003, Merrill analysts said. Merrill Lynch, which commissioned a research firm to get doctor feedback, reportedly found that Celexa has fewer serious side effects, including incidences of sexual dysfunction and drug interactions.